In support of this statement are some clinical findings indicating that patients with breast cancers lacking a functioning p53/pRb pathway and treated with the adjuvant standard chemotherapy regimen, which includes 5-FU and methotrexate, had a more favorable clinical outcome in comparison with patients with cancers with a normally functioning p53/pRb pathway [14, 15]. Here, RB1 is linked to breast carcinoma.